Effect of human albumin infusion on inflammation, oxidative stress, and prognosis in decompensated cirrhosis: a prospective cohort study with a meta-analysis

作者：Haonan Zhao, Liyan Dong, Lin Guo, Siqi Jia, Junxiu Chen, Zhuang Liu, Feng Ji, Wenxiu Zhang, Yue Hou, M Bernardi, Xingshun Qi · 发表于：BMC Gastroenterology · 年份：2026 · DOI：10.1186/s12876-026-04866-7 · 被引用次数：1 · 研究领域：Liver Disease and Transplantation、Trauma, Hemostasis, Coagulopathy, Resuscitation、Acute Kidney Injury Research

BACKGROUND: Human albumin (HA) infusion is beneficial for the management of decompensated cirrhosis, but its mechanism remains unclear. This study aimed to evaluate the effect of HA infusion on systemic inflammation, oxidative stress, and prognosis in decompensated cirrhosis. METHODS: In a cohort study, patients with acute decompensated cirrhosis were enrolled and categorized according to HA infusion. Serum interleukin (IL)-6, IL-10, tumor necrosis factor-alpha (TNF-α), superoxide dismutase (SOD), malondialdehyde (MDA), and glutathione (GSH) levels were measured before and after treatment. We compared the one-year cumulative incidence of further decompensation between the two groups. In a meta-analysis, all relevant papers were systematically searched, and pooled using a random-effects model. RESULTS: In the cohort study, 55 patients were included, of whom 23 received HA infusion. HA infusion significantly reduced IL-6 (92.79 ± 144.14 vs. 66.99 ± 89.61, P = 0.031) and MDA (15.19 ± 8.44 vs. 11.05 ± 6.77, P = 0.006) levels, but increased GSH (135.76 ± 14.91 vs. 142.00 ± 19.69, P = 0.033) level. ∆IL-6 (-25.80 ± 64.28 vs. 1.83 ± 25.05, P = 0.013) and ∆TNF-α (-12.95 ± 28.91 vs. 1.82 ± 11.31, P = 0.037) were greater in the HA group than in the control group. One-year cumulative incidence of further decompensation was significantly lower in the HA group than in the control group (P = 0.036). HA infusion was an independent protective factor of further decompensation (sHR = 0.312, P =...